INTRODUCTION
Estrogen acts in many tissues to alter gene expression through specific nuclear receptors. These receptors bind estrogen, dimerize, and modulate gene transcription through interactions with estrogen response elements (EREs) in the promoter regions of estrogenregulated genes (1) . As a member of the steroid/ thyroid hormone superfamily of nuclear transcription factors, the estrogen receptor (ER) is composed of several distinct functional domains. These include a ligand-independent transactivation function at the N terminus (AF-1), a DNA-binding domain (DBD) that allows dimerization of ERs and binding to EREs in estrogen-regulated genes, and a ligand-binding domain (LBD) near the C terminus (1) (2) (3) . The LBD is important for both ligand-activated transactivation through the AF-2 region and dimerization of ERs (1, 2) . The DBD and LBD both play a role in nuclear localization of ERs (1, 2) .
In addition to the recently described ER isoform ER␤ (4), several variants of the ER␣ have been identified in human breast cancer (5-7) and tumor cell lines (7, 8) . These variants have contained point mutations (5, 9) , exon deletions (7, 8, 10) , and C terminus truncations (6) . Some of these variants can have transcriptional effects (9, 10) . However, except in rare cases these variant ERs represent only a small proportion of ER present in cells (8) . Further, there have been no reports of specific modulation of the levels of these splice variants or mutant receptors in normal tissue. In rats, a number of ER variants have been identified in reproductive tissues (11) (12) (13) . At least some of these rat ERs are highly regulated throughout the estrous cycle and can exceed the levels of full-length ER␣ under physiological conditions (11) (12) (13) .
We identified one such ER␣ variant mRNA and protein in female rat pituitaries (11) . This variant, truncated ER product-1 (TERP-1), encodes a protein that is truncated at the N terminus. The transcribed mRNA contains exons 5-8 of the full-length ER␣ and a 31-bp unique sequence upstream of exon 5, indicating a unique transcriptional start site and promoter. Two in-phase translational start codons are present in exon 5, and immunoblot analysis confirms that TERP-1 protein is translated in vivo in the pituitary (13) , in transfected cells, and in vitro. TERP-1 mRNA expression is also highly regulated by estrogen levels in vivo (11) . In male rats and in ovariectomized female rats, pituitary TERP-1 mRNA levels are very low to undetectable as determined by Northern analysis and ribonuclease (RNase) protection, but treatment with estradiol for 1-3 days increases TERP-1 mRNA up to 7-to 10-fold (11, 13, 14) . A unique property of TERP-1 is its regulation during the rat estrous cycle, when it is stimulated at least 50-fold, which suggests possible important regulatory actions for this ER receptor variant under physiological conditions. Although TERP-1 is essentially undetectable during early diestrus, mRNA levels exceed ER␣ on proestrus (13) . This timing of expression suggests that TERP-1 could modulate estrogen actions around the proestrus gonadotropin/PRL surge. In the pituitary, ER␣ is present primarily in lactotropes and gonadotropes (14) (15) (16) . Recent evidence that TERP-1 is present in ER-containing lactotropes (12, 17) , and possibly gonadotropes (18) , further supports a role in estrous cyclicity in the pituitary. This tissue-specific expression and regulation of TERP-1 distinguishes it from other ER splice variants or mutants.
Although the physiological role of TERP-1 is unknown at the present time, its regulation by estrogen in the pituitary and timing of expression during the estrous cycle suggests that it may play a role in estrogen feedback in pituitary cells. One possible mechanism for such feedback effects would be that TERP-1 could alter expression of estrogen-regulated genes either alone or in concert with ER␣ or ER␤. Because TERP-1 lacks a DBD and a portion of the LBD (based on the predicted translational start site and protein size), it was unclear whether TERP-1 could affect the transcription of estrogen-regulated genes. If TERP-1 is able to influence transcription of estrogen-regulated genes through EREs, it is likely that full-length ERs are a necessary component in TERP-1 actions. In the present study we examined the ability of TERP-1 to alter the transcription of model and natural estrogen-responsive promoters in cell culture and the necessity of full-length ERs and estrogen for TERP-1's actions. We found that TERP-1 could influence the transcription of estrogen-regulated genes. Although TERP-1 alone had no effect on transcription, it had a biphasic action on ERE-containing promoters in the presence of fulllength ERs. Low ratios of TERP-1 to ER (Ͻ1:1) enhanced transcription, whereas higher ratios were inhibitory. The stimulatory effects were both promoter and cell type dependent, whereas the inhibitory actions of TERP-1 were observed in all cell types.
RESULTS

TERP-1 Protein Expression and Estrogen Binding
Protein levels of ER␣ and TERP-1 were assessed in calcium phosphate-transfected Cos-1 cells by immunoblotting. For comparison, in vitro translated ER␣ and TERP-1 are also shown (Fig. 1) . ER␣ was clearly detected as a 64-to 66-kDa protein, and TERP-1 was detected as a pair of doublets at 22-24 kDa, which probably represent translation from two methionines (amino acids 393 and 408) in exon 5. In transfected Cos-1 cells, ER␣ and TERP-1 proteins of this size were also detected (Fig. 1) . The larger protein, corresponding to the 5Ј-translational start site, is preferred in both transfected cells and normal pituitary cells (13) . TERP-1 protein was clearly detectable in cell lysates when concentrations of 500 ng or greater were transfected. The inability to detect TERP-1 protein at lower transfection concentrations may be due to high turnover of the protein or the sensitivity of our antibody at low molar concentrations of TERP-1. However, several such experiments consistently demonstrated that levels of full-length ER␣ (1 g) were relatively constant, even with increasing amounts of TERP-1 protein.
Based on immunoblotting analysis, both full-length ER␣ and transfected TERP-1 were at much lower levels in GH3 cells as compared with Cos-1 cells, even with high transfection concentrations (data not shown). The predicted protein sequence of TERP-1 contains most of the ligand-binding domain of ER␣ (predicted amino acids 393-600 of rat ER␣), and thus TERP-1 might exert some transcriptional effects through estrogen binding. We assessed estrogen binding in vitro and in transfected Cos-1 cells using either 1 g of ER␣ or 1 g of TERP-1. ER␣ and TERP-1 were in vitro translated using coupled transcription-translation from rabbit reticulocyte lysate. Lysates (10 l) were incubated with 0.05 pmol [ 3 H]-estradiol (E 2 ) and 5 pmol of unlabeled diethylstilbestrol (DES), and binding was determined using the hydroxylapatite method (19) . E 2 binding by ER␣ was readily displaced by DES, whereas TERP-1 showed no specific binding ( Fig. 2A) (Fig. 2B ). In agreement with the in vitro experiments, TERP-1 did not bind E 2 (Fig. 2B) .
TERP-1 Effects on Transcription in Cell Lines
We first tested TERP-1 transcriptional effects in the ER-negative Cos-1 cell line using model promoters containing two consensus vitellogenin EREs upstream of either a TATA box (2EREpGL2) or the thymidine kinase promoter (Vit6luc) fused to a luciferase reporter. As shown in Fig. 3A , cotransfection of 1 g of an expression vector for full-length rat ER␣ and treatment of transfected cells with 10 nM E 2 stimulated 2EREpGL2 approximately 7-fold and Vit6luc approximately 2.5-fold. Cotransfection of 1 g ER␣ and 100 ng of TERP-1 increased expression of 2EREpGL2 and Vit6luc above that seen with ER␣ alone. The effect is specific to ER-mediated transcription, as TERP-1 did not alter the expression of a promoter lacking an ERE, the rat glycoprotein ␣-subunit (Fig. 3A) . However, the response was influenced by the promoter context, as TERP-1 enhancement of E 2 /ER␣-stimulated transcription was greater for the Vit6luc reporter than the 2EREpGL2 (Fig. 3A) . TERP-1 also enhanced ER␤-stimulated transcription of Vit6luc in Cos-1 cells, but this response was less than for ER␣ (Fig. 3A) . The effect of TERP-1 on transcription of both model promoters was biphasic. Figure 3B shows an example of this response with the 2EREpGL2 promoter in Cos-1 cells. Stimulatory responses with TERP-1 occurred at transfected TERP-1 to ER ratios of Ͻ1:1. The amount of transfected TERP-1 needed for optimal stimulation of ER-mediated transcription was not absolute, possibly due to efficiency of transfection or resulting levels of TERP-1 protein translated. However, the amount of TERP-1 that enhanced transcription was directly related to the amount of ER␣, increasing with higher levels of ER␣ transfected (data not shown). TERP-1 to ER ratios of 1:1 had either no net effect on E 2 /ERstimulated transcription or were inhibitory (Fig. 3B) , and TERP-1 to ER ratios Ͼ1:1 inhibited ER-induced transcription (Fig. 3B) .
Physiologically, TERP-1 is highly expressed in the pituitary, and given its induction by E 2 we expect TERP-1 protein to be present in lactotropes and gonadotropes. Recent experiments confirm that TERP-1 mRNA is present in lactotropes (12, 17) . Therefore, we examined the ability of TERP-1 to alter transcription in pituitary cell lines that contain endogenous ER. In the presence of 10 nM E 2 , the endogenous ER modestly stimulated transcription of model promoters in the mouse ␣T3 gonadotrope cell line, and TERP-1 enhanced E 2 /ER-stimulated transcription of both Vit6luc and 2EREpGL2 above levels achieved with the endogenous ER alone (Fig. 3C) . Transfection of 1 g or more of TERP-1 was inhibitory (Fig. 3C ). In the presence of 10 nM E 2 , the endogenous ER stimulated transcription of the model promoters in the rat somatolactotrope GH3 cell line less than 2-fold (Fig. 3C) . Transfection of 100 ng of TERP-1 failed to enhance this effect (Fig.  3C ), although higher concentrations of TERP-1 were inhibitory (Fig. 3C) . Therefore, we also tested TERP-1 effects on a natural pituitary promoter in a pituitary cell line, and we used a rat PRL reporter (PRLluc) for this purpose. This PRL promoter construct contains 2.5 kb of the physiological promoter with a composite ERE that requires the transcription factor Pit-1 for optimal E 2 induction (20) . The addition of 10 nM E 2 increased expression of PRLluc 5-fold (Fig. 3C ). As we observed in Cos-1 cells using model promoters, TERP-1 enhanced this estrogen-induced effect at low concentrations of transfection (Fig. 3C) . However, the stimulatory effect of TERP-1 on PRLluc was much smaller, averaging 50% (Fig. 3C) . Transfection of 1 g of TERP-1 failed to enhance E 2 /ER-stimulated transcription (Fig. 3C) , and higher doses of TERP-1 were inhibitory (data not shown).
Role of Hormone and ER in the TERP-1 Transcriptional Response
To test the requirement for full-length ER␣ and hormone in mediating the effects of TERP-1, stimulation of the Vit6luc promoter was measured in Cos-1 cells. Transfection of TERP-1 at concentrations up to 2 g in the absence of ER␣ had no influence on promoter activity, demonstrating a dependence on ER-induced transcription (Fig. 4) . TERP-1's stimulatory actions were also dependent on estrogen. Both the selective ER antagonist 4-hydroxy-tamoxifen and the antiestrogen ICI 182,780 antagonized TERP-1-enhanced E 2 -stimulated transcription in Cos-1 cells (Fig. 5 ). These data demonstrate a dependence on ligand-activated ER for TERP-1's stimulatory actions.
Based on its predicted structure, TERP-1 contains one of two heterodimerization regions of the full-length receptor and may interact directly with full-length ER␣. Coimmunoprecipitation studies of ER␣ and TERP-1 were performed with both in vitro translated proteins Open bars represent transcriptional responses of ERE-containing reporters (1 g of 2EREpGL2 or Vit6luc) and a reporter lacking an ERE (␣3luc) to 1 g transfected ER␣ or ER␤ in the absence of E 2 . Hatched bars represent the same conditions after 6 h of treatment with 10 nM E 2 . Solid bars represent 6 h of E 2 treatment in cells cotransfected with reporter, ER, and 100 ng TERP-1. In each case, E 2 treatments were normalized to the untreated condition and represent the mean Ϯ SD of triplicate measurements. B, TERP-1 dose response in transfected Cos-1 cells using the 2EREpGL2 reporter (1 g) cotransfected with 1 g ER␣ and increasing concentrations of TERP-1 (1 ng to 10 g). The open bar represents transfection in the absence of E 2 , and solid bars represent 6 h treatment with 10 nM E 2 normalized to the untreated condition. Each bar represents the mean Ϯ SEM of three independent experiments with individual experiments performed in triplicate. C, Representative experiments showing the effect of 100 ng or 1 g TERP-1 on ERE-containing reporters (1 g Vit6luc or PRLluc) in ␣T3 and GH3 pituitary cell lines. Bars are the same as in panel A, with the addition of stippled bars to represent the effect of 1 g of TERP-1. ␣T3 cells were treated with or without 10 nM E 2 for 6 h, GH3 cells for 24 h. In all cases, total transfected DNA was normalized with the pcDNA empty vector. In this and subsequent figures rALU refers to luciferase activity in arbitrary light units corrected for total lysate protein and normalized to the untreated condition (nt). and transfected Cos-1 cells with essentially the same results. Because TERP-1 contains identical sequences to the C terminus of ER␣, the proteins were distinguished by using the hinge antibody ER715, which recognized only the full-length ER␣, and an epitope-tagged construct of TERP-1 (TERP-FLAG). TERP-FLAG contains the eight-amino acid FLAG epitope at the C terminus of TERP-1 and can modulate ER transcriptional activity in Cos-1 cells (not shown). As shown in Fig. 6 , immunoprecipitation studies failed to show a direct interaction between ER␣ and TERP-FLAG (upper panel), although coprecipitation of ER␣ and ER␤ could be demonstrated under these conditions (bottom panel). Thus, under these stringent conditions, TERP-1 does not appear to interact directly with ER␣.
Interaction of TERP-1 with Steroid Receptor Coactivator-1 (SRC-1)
Although TERP-1 does not bind estrogen and does not appear to have a stable direct interaction with the full-length ER␣, it only has transcriptional effects in the presence of a ligand-activated full-length ER. Therefore, it probably acts through other protein-protein interactions. One possible mechanism is titration of inhibitory cofactors such as steroid corepressors or stimulatory coactivators such as SRC-1 (21) receptor interacting protein 140 [RIP140 (22) ]. Experiments with the corepressors N-COR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) suggest that they do not affect estrogen-stimulated transcription by ER␣ (Ref. 23 and our unpublished results), a requirement for TERP-1 actions. However, TERP-1 may interact with a coactivator such as SRC-1, either directly or by competing with SRC-1 for binding partners. We tested the ability of SRC-1 to influence TERP-1 effects on ER␣-mediated transcription. SRC-1 enhanced E 2 /ER␣-stimulated transcription of Vit6luc in transfected Cos-1 cells in a dose-dependent manner (Fig. 7A) . Cotransfection of low levels of TERP-1 (100 ng) did not further enhance SRC-1's effects on E 2 /ER␣-stimulated transcription (Fig. 7A) . However, increasing levels of SRC-1 overcame the inhibitory action of higher levels (2-5 g) of cotransfected TERP-1 (Fig. 7B) . These data suggest that TERP-1 may compete with ER␣ for binding sites on SRC-1 or similar cofactors, thus limiting the extent of ER␣ activation.
DISCUSSION
Previously, we identified a truncated ER mRNA and protein from female rat pituitaries (11). This truncated ER product-1 (TERP-1) cDNA encodes a unique 31-bp 5Ј-end and the intact exons 5-8 of the rat ER␣. Thus, TERP-1 contains most of domain E and all of domain F but has no AF-1 region or DBD. Although two potential in-phase start codons are present near the N terminus of exon 5 and result in two transcripts in vitro, our studies in transfected cells suggest that the first ATG (residue 393) is used preferentially in Cos-1 cells (Fig. 1) , in agreement with our observations in normal pituitary cells (13) .
TERP-1 expression in vivo is localized to the pituitary, where it may play a role in estrogen-regulated gene expression (11) . High TERP-1 mRNA levels are induced by estrogen in castrate male and female rats and during the estrous cycle under conditions where the full-length ER␣ is modulated only slightly (13, 14) . Recent reports and our unpublished observations demonstrate that TERP-1 is localized to pituitary cells that express ER␣, namely lactotropes and gonadotropes (12, 17, 18) . This suggests that TERP-1 is dependent on ligand-bound ER for expression as well as biological activity. Thus, TERP-1 could provide a level of cellular feedback to estrogen-sensitive genes in the pituitary. Our observation that TERP-1 modulated transcription from both heterologous and physiological promoters in pituitary cell lines supports this hypothesis.
Transcriptional activation by naturally occurring truncated or mutant steroid receptors is not uncommon, and the interaction of receptor isoforms may provide an important level of gene regulation. Interestingly, many of these interactions do not require an intact DBD or binding to a hormone response element. Recently a third PR isoform, PR-C, has been identified (24) . Like TERP-1, PR-C is amino truncated and lacks the first zinc finger of the DBD. PR-C is also able to enhance PR-A-and PR-B-induced transcription, although it has no transactivating capacity alone. Other superfamily members also have actions that do not require the complete receptor. For example, the LBD of the 9-cis-retinoic acid receptor (RXR) alone can enhance transcriptional activation by the orphan receptor Nurr1 (25) . Furthermore, although it has no DBD, the orphan receptor SHP has an LBD and dimerizes with other superfamily members, including ER␣ and ER␤, to inhibit transcription (26, 27) . Mutations of the first zinc finger in the glucocorticoid receptor (GR) DBD inhibit DNA binding to glucocorticoid response elements but allow ligand-dependent activation of interleukin-6, a promoter the intact GR suppresses (28) . In addition, ER␣ can activate transcription from elements other than EREs by interacting with other transcription factors, and variant ER forms may play a role in this response. For example, tamoxifen-bound ER␣ can interact with Jun/Jun or Fos/Jun dimers to enhance transcription driven by AP1 (29) , and this effect does require an intact DBD. The estrogen antagonist raloxifene also stimulates ER␤-induced transcription through interactions with Fos and Jun at AP1 sites (30) . These mechanisms of transcriptional activation by steroid receptors demonstrate that various unique promoter sequences may be identified by the combination of receptor isoforms and ligands present in the cell.
The mechanisms by which TERP-1 influences estrogen-regulated gene transcription clearly require a ligand-activated ER. TERP-1 does not bind estrogen itself, but modulates ER␣ or ER␤ stimulated transcription in the presence of estrogen, while antiestrogens prevent TERP-1 effects. TERP-1 effects are not a gen- Hatched bars represent cells transfected with 1 g Vit6luc, 1 g ER␣, 2 g TERP-1, and increasing concentrations of SRC-1 (0, 0.1, 0.25, and 1 g) treated for 6 h with 10 nM E 2 . In all cases the SRC-1 parental pBKcmv empty vector was used to normalize for changes in SRC-1, and pcDNA was used to normalize for total DNA transfected. eral transcriptional phenomenon, as a promoter that does not contain an ERE was not affected by the addition of TERP-1. TERP-1 effects on ER␣ and ER␤ might occur through direct interactions with the activated full-length receptors, or by interactions with coactivator or corepressor proteins that themselves influence ER activity. The inhibition of TERP-1-enhanced E 2 -stimulated gene activation by antiestrogens is consistent with either or both possibilities.
Fawell et al. (31) localized the dimerization domain of the mouse ER␣ in the C terminus. Specifically, amino acids 507-518 are necessary for ligand-induced dimerization, and the homologous region is present in TERP-1. Heterodimerization between receptor isoforms has been noted for several nuclear receptors. The resultant dimers can have transcriptional properties in which the activity of one isoform predominates or may result in modified or enhanced activities. For example, the progesterone receptor isoforms PR-A and PR-B both stimulate transcription from PREs, but have different agonist/antagonist profiles (32) . When PR-A/PR-B heterodimers form, PR-A effects predominate on some promoters, but not others (32) . Similarly, ER␣ and ER␤ form heterodimers, and ER␣ activity can predominate in a promoterdependent manner (33, 34) . A C-terminal truncated form of ER␣, resulting from an exon 5 deletion, was recently reported to stimulate activated ER-dependent promoter activity in osteosarcoma cells (35) . This variant can bind DNA, and may form heterodimers on DNA with full-length ER␣, but cannot bind hormone itself. Thus, the enhanced activity of the heterodimer in the osteosarcoma context may occur through enhanced receptor interactions with the transcriptional machinery or altered interactions with other accessory proteins. Our immunoprecipitation studies do not demonstrate direct interactions between TERP-1 and ER␣, even though ER␣ and ER␤ formed heterodimers under these conditions. This result suggests two possibilities. TERP-1 may interact with ER␣, but under less stringent conditions than tested here, or only as part of a multiprotein complex that is not preserved under immunoprecipitation conditions. Alternatively, TERP-1 may act as an intracellular buffer by binding to cofactors that interact with the C-terminal portion of ER, thus altering the levels of proteins available to interact with full-length ER.
Several steroid receptor cofactors, including those with positive (coactivators) and inhibitory (corepressors) effects on transcription have been identified (36) . ER-stimulated transcription may be enhanced by several coactivators such as steroid-receptor coactivator-1 [SRC-1, (21)], the closely related ER-associated protein, ERAP160 (37, 38) , and receptor-interacting protein 140, RIP140 (39) . Such proteins interact with the ER LBD in a ligand-dependent manner, but do not enhance transcription without ER. Our studies demonstrate that transfected human SRC-1 can enhance rat ER␣ activity, as has been noted for the human (40) and mouse (34) ER. Low levels of TERP-1 did not increase ligand-activated ER␣-stimulated transcription above levels observed with SRC-1 alone. However, the enhancement of ER activity by TERP-1 may occur by titration of corepressor proteins. Such proteins have been identified for ER␣ (41) , PR (41) , and TR (42, 43) . A potential novel ER-specific repressor, which binds to the LBD of the ER without the hinge region, has also recently been described from MCF7 breast cancer cells (44) and could represent one of many possible cell-specific cofactors influencing ER action. The interaction of TERP-1 with corepressor proteins is consistent with our results in that binding of estrogen and SRC-1 alone may reduce the influence of corepressors on ER-mediated transcription to the point that TERP-1's effects are negligible.
Increasing concentrations of SRC-1 can overcome the inhibitory effect of TERP-1. One potential mechanism is a direct interaction between TERP-1 and SRC-1. Evidence for such an interaction comes primarily from studies of TR␤. Recent data from Feng et al. (45) shows that mutations in amphipathic helices 3, 5, 6, and 12 of TR␤ diminish the binding of glucocorticoid receptor-interacting protein 1 (GRIP1) and SRC-1. The same mutations reduced transactivation by TR␤ (45) . Three similar mutations in helices 3, 5, and 12 of human ER␣ decreased GRIP1 binding and hormone-dependent transactivation (45) . The authors suggest that all three regions are needed for coactivator binding and full receptor activity. TERP-1 contains only one of these regions, helix 12. However, Jeyakumar et al. (46) recently demonstrated that a 20-amino acid peptide (a.a. 437-456) of TR␤ reduced SRC-1 binding to TR␤ by 80%. Thus, TERP-1 might be able to serve an analogous inhibitory role in certain cell contexts. Cell and promoter-dependent responses we observed could result from the relative contribution of such cofactors to ER-mediated transcription of individual promoters and the relative concentration of specific cofactors, ER and TERP-1, in different cell lines.
The expression and regulation of TERP-1 in vivo suggests that it may play a role in estrogen feedback in the female rat pituitary during the estrous cycle. The present study demonstrates that low ratios of TERP-1:ER enhance E 2 -stimulated gene expression in cell lines transiently transfected with ER␣ or ER␤ and in cell lines expressing endogenous ER␣. However, TERP-1 inhibits E 2 -stimulated gene expression at higher ratios. TERP-1 appears to modulate transcription of model promoters and a physiological promoter in an estrogen-and ER-dependent manner. The ability of TERP-1 to both enhance and inhibit transcription allows for the possibility that the dynamic regulation of TERP-1 during the estrous cycle leads to both enhancement and inhibition of estrogen actions in the pituitary. It is important to note that in E 2 -treated rats TERP-1 mRNA levels are similar to those observed during proestrus, and TERP-1 protein is readily detected in the pituitaries of E 2 -treated rats at nearmolar equivalence with ER␣ (13) . In the present study, TERP-1 protein levels in transiently transfected Cos-1 cells were well below the levels of ER␣, even when greater amounts of TERP-1 plasmid were transfected (Fig. 1) . These observations suggest that in vivo TERP-1 may play a predominantly inhibitory role. The results of the present study suggest that TERP-1 may act via protein-protein interactions rather than direct high-affinity interactions with ER. Thus, the truncated receptor could act as a buffer to modulate the levels of coactivators and corepressors available for interaction with the full-length ER, and thereby modify its transcriptional activity.
MATERIALS AND METHODS
Cell Culture and Transfections
The monkey kidney Cos-1, ER-negative cell line was maintained in DMEM supplemented with 10% newborn calf serum (NCS), 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were plated in phenol-red free DMEM/3% charcoal-stripped NCS in 30-mm wells and grown to 60-80% confluence before transfection by the calcium phosphate method (47) . Each well was transfected with a total of 5 g DNA for 14-17 h, washed with PBS, and treated with hormone or drugs for 6-8 h before being lysed and collected for assessment of luciferase activity. The ER-containing GH3 rat somatolactotrope cell line was maintained in DMEM/10% NCS and transfected by the diethylaminoethyl (DEAE)-Dextran method (48) . Cells were plated in phenol-red free DMEM/10% stripped NCS in 60-mm wells and allowed to grow to 40-50% confluence before transfection. Media were removed, and cells were washed with PBS before 2 h of treatment with DNA in DEAEdextran. After removal of DEAE-dextran, cells were treated for 2 min with 10% dimethylsulfoxide in HEPES-buffered saline, washed with PBS, and treated with hormones or drugs in media for 24 h. AlphaT3 (␣T3) cells (49) , an ER-expressing gonadotropin cell line of murine origin, were maintained in DMEM/10% FCS and plated and transfected with calcium phosphate as described for Cos cells. Cell culture media and sera were purchased from GIBCO-BRL (Gaithersburg, MD). 
Plasmids
TERP-1 and full-length rat ER␣ cDNAs were isolated from female rat pituitaries by 5Ј-rapid amplification of cDNA ends (11) and cloned into a pcDNA expression vector (Invitrogen Corp., San Diego, CA) under the control of the cytomegalovirus (CMV) promoter. The full-length rat ER␤ clone in the pCMV5 expression vector was obtained from Dr. Deborah Lannigan. The SRC-1 expression vector was obtained as a gift from Dr. Bert O'Malley. All reporter plasmids contained the luciferase reporter gene. Two simple reporter plasmids containing model estrogen-responsive promoters were used in these studies. (ERE)2-vit-TK-luc (Vit6luc) contained two vitellogenin consensus EREs and the thymidine kinase promoter. 2EREpGL2 was kindly provided by Dr. Deborah Lannigan and contained two consensus EREs upstream of a TATA box minimal promoter. One physiological estrogenresponsive reporter plasmid, PRL luc Link V2 (PRLluc, gift of Dr. Richard N. Day), containing 2.5 kb of the rat PRL promoter was also used. A rat glycoprotein ␣-subunit promoter construct (Ϫ411 to ϩ77 bp) cloned in our laboratory [␣3-luc (50)] and lacking EREs was used as a control for ERE dependence. To normalize the total plasmid DNA concentrations used in transfections, the empty pcDNA vector was used. In experiments with SRC-1, the pBKcmv empty vector was used to normalize total DNA (21) . Luciferase activity was assessed on a Turner-20E luminometer using a Promega (Madison, WI) luciferase assay kit, and samples were normalized by assessing lysate protein with Bio-Rad (Hercules, CA) protein dye. Data are presented as relative arbitrary light units, normalized to the estrogen-negative condition. Values represent the mean Ϯ SD of triplicate samples, unless otherwise noted.
Estrogen Binding Assay
Estrogen binding of ER␣ and TERP-1 was assessed in vitro and in transfected Cos-1 cells. ER␣ and TERP-1 were in vitro translated using coupled transcription-translation from rabbit reticulocyte lysate (TNT kit, Promega). Lysates (10 l) were incubated with 0.05 pmol [ 3 H]E 2 and 5 pmol of unlabeled DES in triplicate at 4 C for 4 h. Bound and free E 2 were separated using the hydroxylapatite method (19) , and 200-l aliquots in 10 ml of ReadySafe scintillation fluid (Beckman Instruments, Fullerton, CA) were counted in an LKB Rackbeta scintillation counter (LKB Instruments, Rockville, MD). We assessed estrogen binding in calcium phosphate-transfected Cos-1 cells using either 1 g of ER␣ or 1 g of TERP-1. Cells were plated in DMEM/3.3% charcoal-stripped NCS in 30-mm wells. Media were changed daily for 3 days before transfection. Cells were transfected for 16 h. Media were removed, the cells washed with PBS, and wells filled with serumless, phenol-red free DMEM. Cells were incubated for an additional 24 h before estrogen binding was assessed.
Estrogen binding was determined with a competition assay. Cells were treated with 1 nM [2,4,5,6-3 H]E 2 (New England Nuclear, specific activity ϭ 114 Ci/mmol) and varying amounts of unlabeled E 2 . Cells were incubated for 1 h at 37 C, rinsed twice with PBS/0.1% BSA and twice with PBS, and collected in 10:1 Tris-EDTA (pH 8). Cells were then sonicated for 20 sec with a Fisher sonic dismembrator, and 200 l of each extract were added to 10 ml of scintillation fluid (ReadySafe; Beckman) and counted in an LKB Rackbeta scintillation counter. Specific binding (labeled E 2 Ϫ 1 M unlabeled E 2 ) was calculated, corrected for total protein, and analyzed by Scatchard plots.
Immunoblot Analysis
TERP-1 and ER␣ protein expression in transfected cells was determined by immunoblot analysis using a rabbit polyclonal antibody (C1355) generated against the final 14 C-terminal amino acids of the rat ER␣. The antibody and conditions for Western analysis were determined using in vitro translated TERP-1 and ER␣ and have been described previously (13) . For analysis of cellular expression, Cos-1 cells were transfected with 1 g of ER␣ and varying concentrations of TERP-1 by calcium phosphate for 4 h and allowed to incubate 48 h in DMEM/10% NCS. In some experiments GH3 cells were also analyzed after transfection with TERP-1. Western analysis was performed with enhanced chemiluminescence (Amersham, Arlington heights, IL) using the C1355 antibody at 1:7500 and an horseradish peroxidase-conjugated donkey antirabbit IgG secondary antibody (1:500; Amersham).
Immunoprecipitations
Because TERP-1 contains the identical amino acid sequence as the C terminus of ER␣, it was necessary to differentiate TERP-1 from ER␣ by epitope tagging. PCR was used to add the eight-amino acid FLAG epitope (Eastman-Kodak, Rochester, NY) to the TERP-1 sequence. The resulting PCR product was ligated into the PCR2.1 cloning vector (Invitrogen), sequenced, and then subcloned into the pcDNA expression vector. Proteins were synthesized from ER␣, ER␤, TERP-1, and TERP-FLAG plasmids (1 g each construct alone, or in combination) by in vitro translation using coupled transcription-translation from rabbit reticulocyte lysate (TNT kit, Promega). Each reaction also contained 40 Ci [ 35 S]methionine (New England Nuclear; 1175 Ci/mmol), and 10 nM E 2 . In some experiments, different ER protein isoforms were cotranslated in the same reactions. Results were similar or identical to results with individually translated proteins. Each immunoprecipitation reaction contained 6 l of translated proteins, 1% BSA, and 50 l of a 2ϫ slurry of either anti-FLAG M2 affinity gel (VWR), or protein A Sepharose (Pharmacia, Piscataway, NJ) linked to either ER C1355 (C-terminal antibody) or ER715 (gift of Dr. Jack Gorski). ER715 recognizes the hinge region of ER␣ and will recognize only full-length receptor. Beads and antibody were first brought to a 2ϫ slurry with 1.5% Nonidet-P40 (NP-40) in PBS, pH 7.6. The proteins, beads, and antibody were incubated at 4 C for 1 h. After incubation, beads were washed four times with 1.5% NP-40 in PBS and resuspended in 25 l of 1.5% NP-40 in PBS and 25 l of loading buffer (100 mM Tris, pH 6.8, 4% SDS, 20% glycerol, 0.2% bromphenol blue). Samples were boiled for 3 min and subjected to electrophoresis on a 12% acrylamide gel for 4 h at 150 V. Gels were dried and exposed to film overnight.
